EPCT-03. Working together to accelerate the preclinical to clinical translation of drug delivery systems for children’s brain tumours

Campbell, Emma; Aquilina, Kristian; Dandapani, Madhumita; Walker, David; Rahman, Ruman

Abstract

Children's brain tumours are the biggest cancer killer in children and young adults. Several techniques, such as intra-cerebrospinal fluid chemotherapy, ultrasound-mediated blood-brain barrier disruption, convection enhanced delivery, polymer delivery systems, electric field therapy, and intra-arterial and intra-nasal chemotherapy, have the potential to transform the treatment of brain tumours in children. However, there have been very few clinical trials to evaluate these. In 2021, the CBTDDC (Children’s Brain Tumour Drug Delivery Consortium) and the ITCC (Innovative Therapies for Children with Cancer) brain tumour group established a Clinical Trials Working Group comprising international researchers and clinicians to address this issue. This partnership highlighted the main challenges in preclinical to clinical translation of paediatric CNS drug delivery as: (1) a lack of specific funding for prototype development and/or scale-up for clinical trials; (2) difficulties in navigating the regulatory landscape; (3) lack of accurate preclinical models; and (4) increased need for multi-centric working. In response to this, we ran a hybrid workshop in November 2021 on ‘Clinical Trial Readiness for CNS Drug Delivery’. At this workshop, around 50 delegates (comprising clinicians, researchers, trial regulatory experts, policy makers, and representatives from funding organisations, brain tumour charities and industry) came together to discuss issues around funding, preclinical models and regulatory processes. We have established speciality-specific working groups to build on the workshop discussions, with the aim of producing recommendations around the use of preclinical models and drug delivery techniques according to brain tumour type. We have also used the workshop presentations and discussions to create a ‘Roadmap’ document for preclinical to clinical translation, which will be freely shared with the neuro-oncology research community. We continue to liaise with funders and regulatory bodies to address the changes that are needed in these areas. If you would like to join our network, contact: [e-mail]

• Journal Article Type: Meeting Abstract
• Acceptance Date: May 23, 2022
• Online Publication Date: Jun 3, 2022
• Publication Date: Jun 3, 2022
• Deposit Date: Jun 15, 2022
• Publicly Available Date: Jun 21, 2022
• Journal: Neuro-Oncology
• Print ISSN: 1522-8517
• Electronic ISSN: 1523-5866
• Publisher: Oxford University Press (OUP)
• Peer Reviewed: Peer Reviewed
• Volume: 24
• Issue: Supplement 1
• Pages: i36-i36
• DOI: https://doi.org/10.1093/neuonc/noac079.131
• Keywords: Cancer Research; Neurology (clinical); Oncology
• Public URL: https://nottingham-repository.worktribe.com/output/8496760
• Publisher URL: https://academic.oup.com/neuro-oncology/article/24/Supplement_1/i36/6600781